

Triple-helix formation by oligonucleotides containing the three bases thymine, cytosine, and guanine

(triplex/psoralen/DNA sequence recognition/oligonucleotides)

CARINE GIOVANNANGÉLI*, MICHEL ROUGÉE*, THÉRÈSE GARESTIER*, NGUYEN T. THUONG†,
AND CLAUDE HÉLÈNE*

*Laboratoire de Biophysique, Institut National de la Santé et de la Recherche Médicale U. 201, Centre National de la Recherche Scientifique, Unité Associée 481, Muséum National d'Histoire Naturelle, 43, Rue Cuvier, 75231 Paris Cedex 05; and †Centre de Biophysique Moléculaire, 45071 Orléans Cedex 02, France

Communicated by Jean-Marie Lehn, March 30, 1992 (received for review January 6, 1992)

ABSTRACT A homopurine-homopyrimidine sequence of human immunodeficiency virus (HIV) proviral DNA was chosen as a target for triple-helix-forming oligonucleotides. An oligonucleotide containing three bases (thymine, cytosine, and guanine) was shown to bind to its target sequence under physiological conditions. This oligonucleotide is bound in a parallel orientation with respect to the homopurine sequence. Thymines recognize A·T base pairs to form T·A·T base triplets and guanines recognize a run of G·C base pairs to form G·G·C base triplets. A single 5-methylcytosine was shown to stabilize the triple helix when incorporated in a stretch of thymines; it recognizes a single G·C base pair in a run of A·T base pairs. These results provide some of the rules required for choosing the more appropriate oligonucleotide sequence to form a triple helix at a homopurine-homopyrimidine sequence of duplex DNA. A psoralen derivative attached to the oligonucleotide containing thymine, 5-methylcytosine, and guanine was shown to photoinduce cross-linking of the two DNA strands at the target sequence in a plasmid containing part of the HIV proviral DNA sequence. Triplex formation and cross-linking were monitored by inhibition of *Dra* I restriction enzyme cleavage. The present results provide a rational basis for the development of triplex-forming oligonucleotides targeted to specific sequences of the HIV provirus integrated in its host genome.

Short oligonucleotides can bind to the major groove of double-stranded DNA at homopurine-homopyrimidine sequences. This was first demonstrated by sequence-specific cleavage with azidoproflavine used to photoinduce cross-linking of the oligonucleotide followed by alkaline cleavage (1) or EDTA-Fe to induce cleavage under reducing conditions (2). Oligonucleotides containing thymine and cytosine bind in a pH-dependent manner with a parallel orientation with respect to the homopurine strand of homopurine-homopyrimidine sequences on double-stranded DNA (3–12). Cytosine methylation was shown to stabilize these triple helices (5, 6) as previously observed on polydeoxynucleotides with alternating sequences (13).

Purine-rich oligonucleotides can also bind to homopurine-homopyrimidine sequences (14, 15). The third strand binds in an antiparallel orientation with respect to the homopurine sequence in contrast to homopyrimidine oligonucleotides. This orientation was also found with oligonucleotides containing guanine and thymine or guanine, thymine, and adenine (14). However, energy minimization studies in our laboratory have suggested that third-strand orientation might depend on the number of ApG and GpA steps in the

homopurine sequence (16, 17). Here we show that an oligonucleotide containing three bases (thymine, cytosine, and guanine) binds in a parallel orientation with respect to the homopurine sequence of a homopurine-homopyrimidine target of human immunodeficiency virus (HIV) proviral DNA (5'-A₄GA₄G₆A-3' for the purine strand). Binding of this oligonucleotide to its target sequence depends very little on pH. Triple-helical complexes can therefore be formed under physiological conditions by oligonucleotides containing three bases (thymine, cytosine, and guanine) with cytosine (or 5-methylcytosine) to recognize guanine in adenine-rich tracts, guanine to recognize runs of guanine and thymine to recognize runs of adenine.

MATERIALS AND METHODS

Oligonucleotide Synthesis. The oligodeoxynucleotides used in this study were synthesized on a Pharmacia automatic synthesizer. The two complementary 29-nucleotide oligodeoxynucleotides were purified by reverse-phase chromatography and by gel electrophoresis. The unmodified 16-mers were obtained from the Pasteur Institute. The psoralen-oligonucleotide conjugates [Pso-16-mer T^mC(p) and Pso-16-mer T^mCG(p): see sequences in Fig. 2] were synthesized by treating 5-(ω -iodohexyloxy)psoralen with a 16-mer carrying a 5'-thiophosphate group as described (18).

Plasmid. The pLTR plasmid was constructed by insertion of HIVBRUCG provirus fragments (19) into pBR328 by standard procedures. The pLTR plasmid (a gift from H. Hirel from Rhône-Poulenc-Rorer) contained 1440 base pairs (bp) of the proviral HIV DNA.

Footprinting. The 29-mer duplex was 5'-labeled on its pyrimidine-containing strand by T4 polynucleotide kinase (New England Biolabs) using [γ -³²P]ATP. The 5'-labeled 29-mer duplex (containing a 1.3:1 excess of the unlabeled strand) was incubated in the presence of oligonucleotides at 4°C in a buffer containing 10 mM Tris·HCl (pH 7.0), 50 mM NaCl, 10 mM MgCl₂, and 0.5 mM spermine. For footprinting reactions 250 μ M 1,10-phenanthroline, 60 μ M CuSO₄, and 20 mM mercaptopropionic acid was added and incubated for 1 hr at 4°C. Samples were precipitated and washed with ethanol and then loaded on 20% polyacrylamide/7 M urea in a buffer containing 89 mM Tris borate and 12 mM EDTA (pH 8.3).

Cleavage by *Dra* I Enzyme. Enzymatic assays were performed at 30°C in a buffer containing 10 mM Tris·HCl, 10 mM MgCl₂, 50 mM NaCl, 1 mM dithiothreitol, and 0.5 mM spermine. After incubation, the enzymatic reaction was stopped by adding EDTA (25 mM). The restriction enzyme *Dra* I was purchased from Boehringer Mannheim. Experiments with *Dra* I restriction enzyme were carried out with the

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Abbreviations: HIV, human immunodeficiency virus; Cu(OP)₂, copper-1,10-phenanthroline complex.




FIG. 1. (A) Models for T·A·T, C⁺·G·C, G·G·C, A·A·G base triplets within a triple-helix motif. The relative polarities of the phosphodiester deoxyribose backbones are indicated (⊙ and ⊗) with bases in the *anti* conformation. (Left) Third strand is oriented parallel to the homopurine sequence of the DNA target. (Right) Orientation is antiparallel. If bases in the third strand were in the *syn* conformation its orientation would be reversed. (B) Positions of C_{1'} atoms in the plane of base triplets. The C_{1'} atoms of the Watson-Crick strands are fixed to clearly demonstrate the variations in position of the C_{1'} atom in the third strand. Hoogsteen and reverse Hoogsteen refer to the type of hydrogen bonds formed between the third base and the purine of the Watson-Crick base pair; they correspond, respectively, to A (Left and Right). Positions of the C_{1'} atoms were obtained from energy-minimized structures (see ref. 17).

pLTR plasmid, which contained four *Dra* I cleavage sites (see Fig. 5).

Irradiation Conditions. The triple-helix-forming psoralen-oligonucleotide conjugates were tested on *Eco*RI-linearized pLTR plasmid. Irradiation of the triplex was performed with a xenon lamp (150 W) just before *Dra* I cleavage experiments. Light was filtered through a Pyrex filter in a water bath to remove radiations below 310 nm.

Spectroscopic Experiments. Absorbance of the oligonucleotide mixtures was measured at 258 nm as a function of temperature with a Uvikon 820 spectrophotometer. The rate of temperature variation was 0.15°C/min.

RESULTS AND DISCUSSION

Base Triplet Isomorphism and Third-Strand Orientation. The molecular recognition of purines already engaged in a Watson-Crick base pair is based on hydrogen bonding interactions with bases of the third strand. Thymine and adenine can form two hydrogen bonds with an adenine of a Watson-Crick A·T base pair (T·A·T and A·A·T base triplets). Guanine and protonated cytosine can form two hydrogen bonds with a guanine of a Watson-Crick G·C base pair (G·G·C and C⁺·G·C base triplets). These triplets are shown in Fig. 1A. It must be noted that two positions of the third strand are possible for three of these triplets (T·A·T, C⁺·G·C, and G·G·C), corresponding to the so-called "Hoogsteen" or "reverse Hoogsteen" hydrogen bonding pattern, by analogy with the model proposed by Hoogsteen (20) for hydrogen bonding between thymine and adenine. These two positions generate two triple-helical structures with the phosphodiester backbone located either proximal to the purine Watson-Crick strand (Hoogsteen bonds) or at nearly equal distances from the two Watson-Crick strands (reverse Hoogsteen bonds). The A·A·T triplet, which has a single orientation, belongs to the second category.

Fig. 1B shows the positions of the C_{1'} atom of the nucleoside involved in the third strand. It can be seen that only Hoogsteen T·A·T and C⁺·G·C triplets are isomorphous. Even though it could be concluded that an oligonucleotide containing guanine and thymine would exhibit a less distorted backbone if G·G·C and T·A·T base triplets adopted the reverse Hoogsteen configuration (Fig. 1B), energy minimization studies show that Hoogsteen base triplets are energetically more favorable for runs of T·A·T or G·G·C base triplets (16, 17). Therefore, one might expect that the orientation of the third strand should depend on the number of GpT and TpG steps in the third strand. This has been experimentally verified in our laboratory and has led to the development of "switch" oligonucleotides that can recognize two consecutive homopurine sequences, each of them belonging to a different strand of the double helix (16).

Triple-Helix Formation by Thymine-Rich Oligonucleotides. The HIV genome contains two repeats of a 16-nucleotide polypurine sequence; one is present on the 5' side of the U3 sequence in the *nef* gene (positions 8662–8677 in HIV-BRUCG) and the second copy is present in the *pol* gene (positions 4367–4382) (19). The first one is present in pLTR as a 16-bp homopurine-homopyrimidine sequence overlapping a *Dra* I cleavage site (see Fig. 5) and was chosen as a target for triple-helix formation.

We first studied the adenine-rich tract part of the targeted sequence. A 10-bp target (see sequence in Fig. 3A) was used to compare the binding of three decamers called 10-mer TC(p) (5'-T₄CT₄C-3'), 10-mer TG(p) (5'-T₄GT₄G-3'), and 10-mer TG(ap) (5'-GT₄GT₄-3') where (p) and (ap) refer to parallel and antiparallel orientation with respect to the homopurine target strand, respectively (Fig. 2). Absorption melting experiments were performed at pH 6.8 (Fig. 3A). The same melting curves were obtained with both 10-mers TG(p)




FIG. 4. Triple-helix stability. (Upper) Sequence of the double-stranded DNA target. The 16-bp homopurine-homopyrimidine sequence is boxed. (Lower) pH dependence of the temperature of half-dissociation of the third strand (t_m). Melting curves were measured in a pH 6.5 buffer containing 10 mM sodium cacodylate and 10 mM MgCl₂. Triplex mixtures were obtained by mixing equimolar amounts of the three strands (1.2 μ M). Δ , 16-mer TC(p); \square , 16-mer T^mC(p); \circ , 16-mer T^mCG(p).

gave more stable complexes than did the 16-mers TC(p) and T^mC(p). Triple-helix stability was only slightly dependent on pH for the 16-mer T^mCG(p), whereas the 16-mers TC(p) and T^mC(p) bound in a strongly pH-dependent manner due to the requirement for protonation of cytosines to form two hydrogen bonds with G-C base pairs. The same results were obtained by using *Dra* I restriction enzyme cleavage of the 29-bp fragment as a probe of triplex stability (data not shown). Multivalent cations such as spermine or Mg²⁺ were necessary for binding of this guanine-rich oligonucleotide.

The 16-mer T^mCG(p) contains two steps associated with an energy cost due to the lack of isomorphism of base triplets: the central TpG step and the 3'-terminal GpT step. It was expected that the central 5'-TpG-3' step would be easily accommodated due to the stability of the triple helices formed by T₄^mCT₄ and G₆ on its 5' and 3' sides, respectively. On the contrary, the terminal GpT step should not be favorable to the formation of the last T·A·T triplet. Footprinting studies using Cu(OP)₂ as a cleaving agent were in agreement with these conclusions (data not shown). In some further experiments, we therefore used a 15-mer T^mCG(p) lacking the terminal thymine. This 15-mer has the same t_m as the 16-mer T^mCG(p).

Specificity of Binding of the 15-Mer and 16-Mer Containing Thymine, Cytosine, and Guanine. To illustrate the specificity and the stability of the triplex formed by 15-mer T^mCG(p) at physiological pH (pH 7.5), *Dra* I cleavage inhibition assays were performed by using as a substrate the pLTR plasmid containing part of the HIV genome with the 16-bp homopurine-homopyrimidine sequence (positions 3526–3541 in pLTR), which overlaps one of the four *Dra* I cleavage sites (5'-TTTAAA-3') (Fig. 5).

The cleavage reaction products have lengths of 412, 692, 19, 2403, and 974 bp for the plasmid linearized at the *Eco*RI site (position 0). For one of these sites (position 3526), the *Dra* I recognition sequence overlaps by 3 bp the 16-bp oligonucleotide binding site. If *Dra* I could no longer recognize and cleave this site in the presence of a triplex-forming




FIG. 5. (Upper) Schematic representation of pLTR plasmid linearized at its *Eco*RI site. Positions of *Dra* I cleavage on *Eco*RI-linearized plasmid are indicated together with the lengths of cleavage products. *Dra* I enzyme cuts in the center of the sequence 5'-TTTAAA-3'. The triple-helix site is boxed. (Lower) Specific inhibition of *Dra* I cleavage on the pLTR linear plasmid. The plasmid (10 nM) was incubated in the absence of any third strand (lane 4) or in the presence of Pso-16-mer T^mC without irradiation (lanes 1–), 16-mer T^mC(p) (lanes 2), 16-mer T^mCG(ap) (lane 3), 15-mer T^mCG(p) (lanes 5), Pso-16-mer T^mCG(p) without irradiation (lanes 6– and 7–), or with irradiation (lanes 7+). Enzymatic assays were performed at 30°C in a pH 7.5 buffer containing 10 mM Tris-HCl, 10 mM MgCl₂, 50 mM NaCl, 1 mM dithiothreitol, and 0.5 mM spermine. After incubation of each third strand at 30 μ M (lanes 1–6) or 3 μ M (lanes 7) with its double-stranded target, *Dra* I (1.4 units/ μ l) was added and the enzymatic reaction was stopped by adding EDTA (25 mM) after 15 or 30 min (lanes A and B, respectively). Samples were then loaded on a 1.2% nondenaturing agarose gel. Irradiation was performed (lanes 7+) just before *Dra* I cleavage experiments at 30°C for 5 min to ensure that the photoreaction had reached its plateau. Lane M, λ DNA/*Bst*EII digest.

oligonucleotide, the lengths of the generated fragments should be 412, 692, 19, and 3377 bp (2403 + 974).

The plasmid was incubated at pH 7.5 and 30°C in the absence of the third strand (Fig. 5, lane 4) or in the presence of 30 μ M 16-mer T^mC(p) (lanes 2), 16-mer T^mCG(ap) (lane 3), or 15-mer T^mCG(p) (lanes 5) and then a *Dra* I cleavage reaction was performed for 15 (lanes A) or 30 (lanes B) min. The 3377-bp fragment was obtained only for the triplex formed with the 15-mer T^mCG(p) (lanes 5). After longer incubation times of *Dra* I (lane 5B) the intensity of the 3377-bp fragment decreased, whereas that of the 2403- and 974-bp fragments increased. With the duplex-triplex equilibrium being dynamic, the enzyme eventually cleaved when incubated for a long period of time; only a transient inhibition was observed. Under our experimental conditions (pH 7.5 and 30°C), the complex formed by the 16-mer T^mC(p) with its 16-bp target sequence was too weak to allow any *Dra* I cleavage inhibition (lanes 2); the *Dra* I cleavage reaction was as complete as in the control (lane 4).

Irreversible Sequence-Specific Cross-Linking of a Psoralen-Substituted Oligonucleotide Containing Thymine, Cytosine, and Guanine. To obtain an irreversible triple-helical complex, the third strand was attached to a photoactivatable reagent. We previously showed that a psoralen-substituted oligonucleotide containing thymine and 5-methylcytosine could be

cross-linked to both DNA strands under UV irradiation of a triple-helical complex (18). This reaction required attachment of the psoralen via its C-5 position in order to bring psoralen in the appropriate orientation to form cyclobutane rings with two thymines, one on each strand. Conjugation of the same psoralen derivative was carried out with both 16-mer T^mC(p) and 16-mer T^mCG(p) (see *Materials and Methods*).

In the absence of irradiation, covalent linkage of the psoralen derivative to the 5' end of the third strand led to an enhancement in triplex stability due to intercalation of the psoralen at the triplex-duplex junction (Fig. 5: compare lanes 1 to 2 and lanes 6 to 5). However, even if the complex formed between the Pso-16-mer T^mCG(p) and the 16-bp homopurine-homopyrimidine target in the pLTR plasmid was strong enough to inhibit *Dra* I cleavage at pH 7.5 and 30°C in the micromolar range (lanes 7-), *Dra* I eventually cleaved the TTTAAA sequence overlapping the homopurine stretch of the pLTR plasmid after long incubation times. But upon irradiation above 310 nm, the triplex became irreversibly trapped (compare lanes 7+ and 7-). Consequently, an almost complete inhibition of *Dra* I cleavage was obtained (lanes 7+).

CONCLUSION

We have shown that a triplex-forming oligonucleotide containing the three bases thymine, methylcytosine, and guanine (5'-T₄^mCT₄G₆-3') binds to duplex DNA at a specific homopurine-homopyrimidine sequence. The orientation of the third strand is parallel with respect to the homopurine strand involved in Hoogsteen hydrogen bonding.

The actual orientation of a third strand containing thymine and guanine is dependent on the number of GpA and ApG steps present in the homopurine sequence; each such step is associated to a backbone distortion since nonisomorphous base triplets are involved (Fig. 1). It appears that the antiparallel orientation is favored when there are many GpA and ApG steps in the homopurine-targeted sequence, whereas a parallel orientation should be obtained with few ApG and GpA steps. The orientation giving the highest affinity (parallel or antiparallel) of oligonucleotides containing thymine and guanine remains to be elucidated for each triple-helix motif (16).

The results presented in this study provide some rules for the choice of the sequence of the third strand. An isolated guanine in stretches of adenine is better recognized by 5-methylcytosine than by guanine. A stretch of guanines in the homopurine sequence forms a stronger complex under physiological conditions if the third strand contains guanines rather than cytosine (or 5-methylcytosine). A stretch of adenines followed by a stretch of guanines is recognized by an oligonucleotide containing thymine (to form T·A·T triplets) and guanine (to form G·G·C triplets) with the orientation of the third strand parallel to the homopurine sequence.

The results presented in this study show that an oligonucleotide containing thymine, 5-methylcytosine, and guanine provides a good stability of triple-helical complexes on a

proviral HIV sequence. This oligonucleotide binds under physiological conditions to its target sequence. Its binding can be strongly enhanced by attaching an intercalating agent to the 5' end of the third strand (5, 22). Attachment of a psoralen derivative leads to efficient photoinduced cross-linking of the oligonucleotide to its target sequence at the 5'-TpA-3' step that flanks the homopurine sequence on the 5' side. These results provide a rational basis for exploring the possibility of targeting proviral HIV DNA site specifically in HIV-infected cells.

This work was supported by the Agence Nationale de Recherche sur le SIDA and by Rhône-Poulenc-Rorer.

1. Le Doan, T., Perrouault, L., Praseuth, D., Habhoub, N., Decout, J. L., Thuong, N. T., Lhomme, J. & Hélène, C. (1987) *Nucleic Acids Res.* **15**, 7749.
2. Moser, H. E. & Dervan, P. B. (1987) *Science* **238**, 645-650.
3. Praseuth, D., Perrouault, L., Le Doan, T., Chassignol, M., Thuong, N. T. & Hélène, C. (1988) *Proc. Natl. Acad. Sci. USA* **85**, 1349-1353.
4. Strobel, S. A., Moser, H. E. & Dervan, P. B. (1988) *J. Am. Chem. Soc.* **110**, 7927-7929.
5. Sun, J. S., Francois, J. C., Montenay-Garestier, T., Saison-Behmoaras, T., Roig, V., Thuong, N. T. & Hélène, C. (1989) *Proc. Natl. Acad. Sci. USA* **86**, 9198-9202.
6. Povsic, T. J. & Dervan, P. B. (1989) *J. Am. Chem. Soc.* **111**, 3059-3061.
7. Francois, J. C., Saison-Behmoaras, T., Thuong, N. T. & Hélène, C. (1989) *Biochemistry* **28**, 9617-9619.
8. Francois, J. C., Behmoaras, T., Chassignol, M., Thuong, N. T. & Hélène, C. (1989) *J. Biol. Chem.* **264**, 5891-5898.
9. Cooney, M., Czernuszewicz, G., Postel, E. H., Flint, J. & Hogan, M. E. (1988) *Science* **241**, 456-459.
10. Lyamichev, V. I., Mirkin, S. M., Kamenetskii, M. D. & Cantor, C. R. (1988) *Nucleic Acids Res.* **16**, 2165-2178.
11. De Los Santos, C., Rosen, M. & Patel, D. (1989) *Biochemistry* **28**, 7282-7289.
12. Rajagopal, P. & Feigon, J. (1989) *Nature (London)* **339**, 637-640.
13. Lee, J. S., Woodsworth, M. L., Latimer, L. J. P. & Morgan, A. R. (1984) *Nucleic Acids Res.* **12**, 6603-6614.
14. Durland, R. H., Kessler, D. J., Gunnell, S., Duvic, M., Pettitt, B. M. & Hogan, M. E. (1991) *Biochemistry* **30**, 9246-9255.
15. Beal, P. A. & Dervan, P. B. (1991) *Science* **251**, 1360-1363.
16. Sun, J. S., de Bizemont, T., Montenay-Garestier, T. & Hélène, C. (1991) *C.R. Acad. Sci. Paris Ser. 3* **313**, 585-590.
17. Mergny, J. L., Sun, J. S., Rougée, M., Montenay-Garestier, T., Barcelo, F., Chomilier, J. & Hélène, C. (1991) *Biochemistry* **30**, 9791-9798.
18. Takasugi, M., Guendouz, A., Chassignol, M., Decout, J. L., Lhomme, J., Thuong, N. T. & Hélène, C. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 5602-5606.
19. Wain-Hobson, S., Sonigo, P., Danos, O., Cole, S. & Alizon, M. (1985) *Cell* **40**, 9-17.
20. Hoogsteen, K. (1959) *Acta Crystallogr.* **12**, 822-823.
21. François, J. C., Saison-Behmoaras, T. & Hélène, C. (1988) *Nucleic Acids Res.* **16**, 11431-11440.
22. Sun, J. S., Giovannangéli, C., François, J. C., Kurfurst, R., Montenay-Garestier, T., Saison-Behmoaras, T., Thuong, N. T. & Hélène, C. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 6023-6027.